Late last year, Julie Dehaene-Puype stepped into the role of Regional President at Kyowa Kirin International (KKI), a ...

Boston, USA-based Cue Biopharma announced that it will receive a $7.5 million pre-clinical milestone payment under its ...

Boston, USA-based biotech Life Biosciences, which is pioneering cellular rejuvenation therapies to reverse and prevent ...

The US Food and Drug Administration (FDA) has outlined a number of legislative proposals in its fiscal 2027 budget request.

Privately-held Alloy Therapeutics, a biotech ecosystem company promising to democratize access to new drug discovery ...

German drug developer Evotec (FRANKFURT: EVT) reported fourth-quarter 2025 revenue of $293 million, up 14%, and adjusted ...

Chinese nuclear medicine company New Radiomedicine Technology (NRT) has raised more than 1 billion yuan ($145.3 million) in a ...

Japanese pharma major Shionogi today revealed it has been awarded a contract through the Biomedical Advanced Research and ...

Rare disease drug pricing has long rested on a simple trade-off. Small patient populations and high development costs ...

Swiss specialty pharma firm Ewopharma said its partnered immunotherapy sugemalimab has secured a Category I, A recommendation ...

US biotech Insmed (Nasdaq: INSM) has halted development of Brinsupri (brensocatib) in hidradenitis suppurativa after the drug failed a Phase IIb study, missing both primary and secondary endpoints.

Dyno Therapeutics, a privately-held US genetic technologies company applying artificial intelligence (AI) to solve the grand ...